Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects

Inclusion Criteria: * Healthy male and female Caucasian subjects as determined by results of screening * Age ≥ 18 and ≤ 50 years * Broca ≥ - 20 % and ≤ + 20 % * Written informed consent in accordance with Good Clinical Practice and local legislation given Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of gastrointestinal tract (except appendectomy) * Disease of the central nervous system (such as epilepsy) or psychiatric disorders or neurologic disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) (≤ 1 month prior to administration or during the trial, except for oral contraceptives) * Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial except for oral contraceptives) * Participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial) * Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (\> 60 g/day) * Blood donation \> 100 ml (≤ 4 weeks prior to administration or during the trial) * Excessive physical activities (≤ 10 days prior to administration or during the trial) * Any laboratory value outside the reference range of clinical relevance * Females only: * no reliable contraception (e.g. oral contraceptives, 3-month injection, intrauterine device, sterilisation) * pregnancy of breast feeding period